Insmed Inc Stock Analysis
INSM Stock | USD 75.16 0.72 0.95% |
Insmed Inc is overvalued with Real Value of 58.05 and Target Price of 42.58. The main objective of Insmed stock analysis is to determine its intrinsic value, which is an estimate of what Insmed Inc is worth, separate from its market price. There are two main types of Insmed's stock analysis: fundamental analysis and technical analysis.
The Insmed stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Insmed is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Insmed Stock trading window is adjusted to America/New York timezone.
Insmed |
Insmed Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.55. Insmed Inc had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of March 2011. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people. To learn more about Insmed Inc call MBA JD at 908 977 9900 or check out https://www.insmed.com.Insmed Inc Investment Alerts
The company reported the previous year's revenue of 305.21 M. Net Loss for the year was (749.57 M) with profit before overhead, payroll, taxes, and interest of 190.23 M. | |
Insmed Inc currently holds about 554.87 M in cash with (536.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
Insmed Inc has a frail financial position based on the latest SEC disclosures | |
Over 99.0% of the company shares are owned by institutional investors | |
Latest headline from thelincolnianonline.com: Insmed Incorporated Shares Sold by FORA Capital LLC |
Insmed Inc Upcoming and Recent Events
22nd of February 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
22nd of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Insmed Largest EPS Surprises
Earnings surprises can significantly impact Insmed's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2013-08-06 | 2013-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2015-05-07 | 2015-03-31 | -0.5 | -0.55 | -0.05 | 10 | ||
2014-05-08 | 2014-03-31 | -0.41 | -0.36 | 0.05 | 12 |
Insmed Environmental, Social, and Governance (ESG) Scores
Insmed's ESG score is a quantitative measure that evaluates Insmed's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Insmed's operations that may have significant financial implications and affect Insmed's stock price as well as guide investors towards more socially responsible investments.
Insmed Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Artisan Partners Limited Partnership | 2024-09-30 | 2.9 M | Macquarie Group Ltd | 2024-06-30 | 2.7 M | Franklin Resources Inc | 2024-09-30 | 2.7 M | Ameriprise Financial Inc | 2024-06-30 | 2.5 M | Suvretta Capital Management, Llc | 2024-06-30 | 2.5 M | Alliancebernstein L.p. | 2024-06-30 | 2.5 M | William Blair Investment Management, Llc | 2024-09-30 | 2.4 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 2.3 M | Hhg Plc | 2024-06-30 | 2.1 M | Vanguard Group Inc | 2024-09-30 | 17.1 M | Blackrock Inc | 2024-06-30 | 14.3 M |
Insmed Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.58 B.Insmed Profitablity
The company has Profit Margin (PM) of (2.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.13.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.66) | (0.70) | |
Return On Capital Employed | (0.64) | (0.61) | |
Return On Assets | (0.56) | (0.59) | |
Return On Equity | 2.26 | 2.37 |
Management Efficiency
Insmed Inc has return on total asset (ROA) of (0.2605) % which means that it has lost $0.2605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 29th of November 2024, Debt To Assets is likely to grow to 0.91, though Net Tangible Assets are likely to grow to (127.7 M).Last Reported | Projected for Next Year | ||
Book Value Per Share | (2.36) | (2.25) | |
Tangible Book Value Per Share | (3.79) | (3.60) | |
Enterprise Value Over EBITDA | (7.75) | (8.14) | |
Price Book Value Ratio | (13.11) | (12.46) | |
Enterprise Value Multiple | (7.75) | (8.14) | |
Price Fair Value | (13.11) | (12.46) | |
Enterprise Value | 746.7 M | 425.4 M |
Leadership at Insmed emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Operating Margin (2.13) | Profit Margin (2.52) | Beta 1.12 | Return On Assets (0.26) | Return On Equity (8.91) |
Technical Drivers
As of the 29th of November, Insmed retains the Risk Adjusted Performance of 0.0087, market risk adjusted performance of 0.0074, and Downside Deviation of 2.43. Insmed technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Insmed Inc variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Insmed is priced fairly, providing market reflects its last-minute price of 75.16 per share. Given that Insmed Inc has jensen alpha of (0.19), we strongly advise you to confirm Insmed Inc's regular market performance to make sure the company can sustain itself at a future point.Insmed Inc Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Insmed middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Insmed Inc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Insmed Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insmed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insmed Outstanding Bonds
Insmed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Insmed Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Insmed bonds can be classified according to their maturity, which is the date when Insmed Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Insmed Predictive Daily Indicators
Insmed intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Insmed stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 15985.98 | |||
Daily Balance Of Power | (0.42) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 75.68 | |||
Day Typical Price | 75.51 | |||
Price Action Indicator | (0.88) | |||
Period Momentum Indicator | (0.72) | |||
Relative Strength Index | 51.45 |
Insmed Corporate Filings
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 16th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 10th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 9th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Insmed Forecast Models
Insmed's time-series forecasting models are one of many Insmed's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Insmed's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Insmed Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Insmed prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Insmed shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Insmed. By using and applying Insmed Stock analysis, traders can create a robust methodology for identifying Insmed entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (2.45) | (2.57) | |
Operating Profit Margin | (2.33) | (2.44) | |
Net Loss | (2.46) | (2.58) | |
Gross Profit Margin | 0.79 | 0.82 |
Current Insmed Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Insmed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Insmed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
42.58 | Strong Buy | 18 | Odds |
Most Insmed analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Insmed stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Insmed Inc, talking to its executives and customers, or listening to Insmed conference calls.
Insmed Stock Analysis Indicators
Insmed Inc stock analysis indicators help investors evaluate how Insmed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Insmed shares will generate the highest return on investment. By understating and applying Insmed stock analysis, traders can identify Insmed position entry and exit signals to maximize returns.
Begin Period Cash Flow | 1.1 B | |
Long Term Debt | 1.2 B | |
Common Stock Shares Outstanding | 140.4 M | |
Total Stockholder Equity | -331.9 M | |
Tax Provision | 2.6 M | |
Property Plant And Equipment Net | 104.4 M | |
Cash And Short Term Investments | 780.4 M | |
Cash | 482.4 M | |
Accounts Payable | 65.4 M | |
Net Debt | 721.6 M | |
50 Day M A | 72.1632 | |
Total Current Liabilities | 225.6 M | |
Other Operating Expenses | 1 B | |
Non Current Assets Total | 400.8 M | |
Non Currrent Assets Other | 96.6 M | |
Stock Based Compensation | 74.8 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.